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INTRODUCTION {#SEC1}
============

Each day, genome integrity is threatened by a multitude of endogenous and exogenous agents than can induce DNA double-strand breaks (DSBs). To neutralize these potentially harmful lesions, cells have implemented diverse mechanisms. One of these, homologous recombination (HR), is an error-free repair pathway that takes place during the S and G2 phases of the cell cycle and allows cells to resolve the damage using the sister chromatid, as a preferred template. Unfortunately, failure to complete HR accurately can lead to cell death or cancer ([@B1]--[@B4]). Some of the central proteins in this process are RAD51, PALB2 (PArtner and Localizer of BRCA2) and BRCA2 (BReast CAncer 2, early onset). Human BRCA2, a 384 kDa protein, exhibits important Breast Cancer (BRC) repeats controlling the function and localization of RAD51 and other components. Mainly, BRCA2 mediator function is needed to bind single-strand (ss) DNA, to interact directly with RAD51 and to stimulate the recruitment of RAD51 by removing Replication Protein A (RPA) from resected DNA ([@B5],[@B6]). RAD51 then searches for homologous sequences ([@B6]), through the invasion of the resected DSB ends into the intact sister chromatid ([@B7]). This process, called D-loop formation, allows one of the two resected DNA ends to be extended using its homologous sequence. PALB2 (Partner and Localizer of BRCA2) protein, another key HR regulator, can also remove the inhibitory effect of RPA and promote RAD51 activity ([@B8]--[@B11]).

The cohesin complex, a ring-like structure, is composed of cohesin proteins (SMC1, SMC3, SCC1 and SCC3) and its regulators (PDS5A/B, SA1/2, NIPBL, WAPL, sororin and SCC4) ([@B12]). This complex is required for the cohesion between sister chromatids after DNA replication. The function of cohesin in DNA repair is mainly linked to its ability to hold sister chromatids together ([@B13]). Nevertheless, cohesin was first discovered as implicated in DNA repair ([@B14]). Moreover, the cohesin complex has a dual function following DNA damage: a direct implication in the repair *per se* and a role in the recruitment of DNA damage checkpoint proteins ([@B15]). Cohesin has recently been shown to repress the C-NHEJ and Alt-NHEJ of distant end-breaks in S/G2 phases ([@B16]). During G1 phase, cohesin is implicated in the class switch recombination (CSR) by modulating non-homologous end-joining (NHEJ) efficiency ([@B17]). Cohesin is also recruited to laser-induced DNA damage ([@B18]). Two cohesin complexes differing by one subunit (SA1 or SA2) are present in somatic cells. Cohesin-SA2 is mainly recruited to DNA damage whereas Cohesin-SA1 is implicated in the intra-S checkpoint ([@B19]). These observations highlight the versatility of the cohesin complex.

Genetic screens in yeast and fungi have identified several classes of cohesion factors, among them is PDS5 for Precocious Dissociation of Sisters ([@B20]). Two PDS5 proteins, PDS5A and PDS5B, are expressed in human cells and interact with cohesin ([@B21]). PDS5B (alternatively named APRIN) belongs to the PDS5 family characterized by the presence of HEAT (Huntingtin, Elongation Factor 3 (EF3), Protein Phosphatase 2A (PP2A), and the yeast kinase TOR1) repeats, known to be involved in protein-protein interactions. ([@B22]). Cells depleted of PDS5B show defects in metaphasic chromosome morphology ([@B21]).

Interestingly, novel roles for APRIN in the DNA damage response were reported. It has been shown that APRIN and other cohesin components associate with BRCA2 in early S-phase. Depletion of APRIN compromises the nuclear localization of RAD51 and BRCA2, disturbs efficient HR and sensitizes cells to DNA damaging agents ([@B23]). Moreover, APRIN expression levels are associated with histological grade of breast cancer and the outcome of breast cancer patients treated with DNA-damaging chemotherapy ([@B23]). The PDS5--BRCA2 complex has also been found to contribute to meiotic recombination at the nuclear envelope by associating with cohesins and lamins ([@B24]). Additionally, PDS5 functions can be regulated by post-translational modifications such as sumoylation, acetylation or phosphorylation ([@B25]--[@B27]). While APRIN has been clearly linked to both cohesion and HR, its precise role in these processes requires better characterization. The roles of PDS5 proteins in cohesion are highly debated, as different teams propose that PDS5 could have positive and negative involvement in the cohesin complex. The role of APRIN outside of its cohesion regulator activity is also poorly understood. While the conceptual implication of APRIN in HR has been characterized, its precise functions in this mechanism still remain elusive.

Here, we provide new and precise mechanistic insights into the role of APRIN in different steps of HR. We have purified APRIN and analysed its DNA-binding properties. We reveal that APRIN has affinity for D-loop structures and ssDNA. APRIN physically interacts with RAD51, PALB2 and BRCA2. APRIN enhances RAD51 DNA strand-invasion activity and catalyzes the annealing of complementary-strand DNA also in synergy with BRCA2. In contrast, we show that APRIN is not involved in NHEJ repair or CSR. Finally, we find that low APRIN expression levels correlate with a better survival in ovarian cancer patients and that APRIN depletion sensitizes cells to Poly(ADP-Ribose) Polymerase (PARP) inhibitor Olaparib *in vivo* in zebrafish xenografts. Our findings establish APRIN as an important regulator of HR with functions outside the cohesin complex.

MATERIALS AND METHODS {#SEC2}
=====================

Cell lines and survival assays {#SEC2-1}
------------------------------

SKOV3 were provided by Anne-Marie Mes-Masson. HEK293T were purchased from ATCC and authenticated. Lentiviruses carrying shRNA constructs (Sigma) were used in order to create cell lines stably expressing shRNA scramble or targeting APRIN or PALB2 mRNA (Pauty, Couturier *et al.*, in preparation). Cell survival was measured using the 3-(4, 5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide (MTT) Cell Proliferation Assay kit of ATCC bio products with AZD2281 (Olaparib, BPS Bioscience, Inc. (27003)) or ABT-888 (Veliparib, Enzo Life Sciences (ALX-270-444)).

Constructs {#SEC2-2}
----------

FLAG/HIS tagged APRIN was cloned by polymerase chain reaction (PCR) amplification of pCMV SPORT plasmid APRIN-myc-his (gift from Peter Geck) into pFastBAC1-52b-GST using the primers cited in Table [1](#tbl1){ref-type="table"}. pEGFP-APRIN was obtained after the insertion of EcoR1/BamH1 PCR products into pEGFP-C1 (Clontech). APRIN deletion constructs were obtained by mutagenesis using the Q5^®^ Site-Directed Mutagenesis Kit (NEB) and primers cited in Table [1](#tbl1){ref-type="table"}. APRIN fragments were cloned by PCR amplification of pCMV SPORT plasmid APRIN-myc-his (gift from Peter Geck) into pEGFP-C1 using primers cited in Table [1](#tbl1){ref-type="table"}. mCherry-PCNA-19-NLS-4 was purchased from Addgene.

###### Primers used for DNA constructs and their sequences

  Protein                                                                           Primers
  --------------------------------------------------------------------------------- -------------------------------------------------------------
  HIS/FLAG APRIN                                                                    JYM 2267, JYM 2268
  **Oligo names**                                                                   **Sequence**
  JYM2267                                                                           ATTCCATGGATTACAAGGATGACGACGATAAGGCTCATTCAAAGACTAGG
  JYM2268                                                                           ATTGCGGCCGCTCGCCGTTCCCTTTTAGCACTT
  **Protein**                                                                       **Primers**
  GFP APRIN                                                                         JYM 2367B, JYM 2368B
  **Oligo names**                                                                   **Sequence**
  JYM2367B                                                                          ATTGAATTCTATGGCTCATTCAAAGACTAGG
  JYM2368B                                                                          ATTGGATCCTCATCGCCGTTCCCTTTTAGC
  **Protein**                                                                       **Primers**
  APRINΔA2                                                                          JYM 2816, JYM 2817
  APRINΔA2                                                                          JYM 2820, JYM 2821
  APRINΔA5                                                                          JYM 2822, JYM 2823
  For these four constructs another PCR step has been done to put back frameshift   
  APRINΔA5 + NLS                                                                    JYM 2824, JYM 2825
  **Oligo names**                                                                   **Sequence**
  JYM 2816                                                                          ACCAATTTTTTTAATCAGGTTCTGATGCTTGGGAAAACATGCTCCTGCAAGCAGGCTGA
  JYM 2817                                                                          TCAGCCTGCTTGCAGGAGCATGTTTTCCCAAGCATCAGAACCTGATTAAAAAAATTGGT
  JYM 2820                                                                          CTAACAACAATATTGCATAGTGATGGAGACATGGAAACTGTAAGCAATGCAAGCAGCAG
  JYM 2821                                                                          CTGCTGCTTGCATTGCTTACAGTTTCCATGTCTCCATCACTATGCAATATTGTTGTTAG
  JYM 2822                                                                          ATTGAATTCATGGCTCATTCAAAGACTAGG
  JYM 2823                                                                          ATTGGATCCTCGTGATGATTTGGTCTGAGA
  JYM 2824                                                                          TCGAGCTAAGCGCCCCGCCGCCACCAAGAAGGCCGGCCAGGCCAAGAAGAAGAAGCA
  JYM 2825                                                                          AAGCTGCTTCTTCTTCTTGGCCTGGCCGGCCTTCTTGGTGGCGGCGGGGCGCTTAG
  JYM 2825                                                                          AAGCTTGCTTCTTCTTCTTGGCCTGGCCGGCCTTCTTGGTGGCGGCGGGGCGCTTAG
  **Fragments**                                                                     **Primers**
  A1                                                                                JYM 2308, JYM 2309
  A2                                                                                JYM 2310, JYM 2311
  A3                                                                                JYM 2312, JYM 2313
  A4                                                                                JYM 2314, JYM 2320
  A5                                                                                JYM 2321, JYM 2322
  **Oligo names**                                                                   **Sequence**
  JYM2308                                                                           ATTGGATCCATGGCTCATTCAAAGACTAGG
  JYM2309                                                                           ATTGCGGCCGCTTATTTCCCAAGCATCAGAAC
  JYM2310                                                                           ATTGGATCCATGACATCTATCAGCGATTTG
  JYM2311                                                                           ATTGCGGCCGCTTATGGACTAACAAGTACTTC
  JYM2312                                                                           ATTGGATCCATGACATGCTCCTGCAAGCAG
  JYM2313                                                                           ATTGCGGCCGCTTAGTCTCCATCACTATGCAA
  JYM2314                                                                           ATTGGATCCATGTTGACAGAACAGGGGAAA
  JYM2320                                                                           AGCTGCTAGCTTTCTTAATAGAATG
  JYM2321                                                                           ATTGGATCCATGGAAACTGTAAGCAATGCA
  JYM2322                                                                           ATTGCGGCCGCTTATCATCGCCGTTCCCTTTT

Generation of SKOV3 GFP-APRIN cell line {#SEC2-3}
---------------------------------------

SKOV3 cells were transfected with pEGFPC1-APRIN using X-tremeGENE 9 (Sigma). Clones were selected under a G418 (450 μg/ml) treatment.

APRIN HIS-FLAG purification {#SEC2-4}
---------------------------

After infection of Sf9 cells with the indicated baculovirus, spinner packaging was centrifuged and pellets were stored at −80°C. Pellets were then lysed with Lysis buffer (50 mM Tris HCl pH 7.5, 150 mM, 10% glycerol, 0.25% Triton X100, 2 mM ethylenediaminetetraacetic acid (EDTA), 1 mM Dithiothreitol (DTT) and Roche protease inhibitors) and dounced 10 times prior to three rounds of 30-s sonication at 4°C. After another douncing step, the mix was centrifuged 30 min (SS-34 fixed angle rotor at 50 000 *g*). Supernatants were incubated with M2 flag beads (Affinity gel Sigma) for 3 h at 4°C. After two washing steps with 250 mM NaCl lysis buffer, the mix was incubated in a Mg/ATP buffer (15 mM MgCl~2~, 5 mM adenosine triphosphate (ATP)) for 30 min at 4°C. Flag peptides (3×) in lysis buffer (500 ng/μl) without EDTA/DTT were used for competitive elutions. Elutions and washes were incubated with TALON beads (Clontech) and P5 buffer (50 mM Na~2~HPO~4~, 50 mM NaH~2~PO~4~, 500 mM NaCl, 10% glycerol, 0.05% Triton X-100, 5 mM Imidazole) for 1 h at 4°C. After two washes with P5 buffer, the bound proteins were eluted with P500 buffer (50 mM Na2HPO4, 50 mM NaH2PO4, 500 mM NaCl, 10% glycerol, 0.05% Triton X-100, 500 mM Imidazole) for 5 min at 4°C. Sample were dialyzed in a storage buffer (20 mM Tris acetate pH 8.0, 200 mM potassium acetate, 1 mM EDTA, 10% glycerol, 1 mM DTT) and stored at −80°C.

Purification of APRIN glutathione S-transferase fragments {#SEC2-5}
---------------------------------------------------------

Recombinant APRIN GST fusions (A1 through A5) were purified from BL21 RP (Stratagene), grown at 37°C in LB medium supplemented with 100 μg/ml ampicillin and 25 μg/ml chloramphenicol. At A600 = 0.4, 0.1 mM Isopropyl β-D-1-thiogalactopyranoside (IPTG) was added to the culture and incubated at 28°C for 4 h. The cells were harvested by centrifugation, frozen on dry ice and stored at −80°C. Pellets were lysed with 10 ml of Lysis buffer (phosphate buffered saline (PBS), 1% triton X-100 and protease inhibitors). Cell lysates were sonicated at 4°C and centrifuged 70 min (SS-34 fixed angle rotor at 50 000 *g*). Supernatants were incubated with 1 ml of Glutathione Sepharose beads 4B (GE Healthcare), 2 h at 4°C. GST was then removed using PreScission Protease (GE Healthcare).

Pull-down assays {#SEC2-6}
----------------

GST-pulldown assays using GST alone, or GST-RAD51 (R51T1-R51T4) and APRIN were performed in 500 μl of R51/B2 buffer (20 mM KH~2~PO~4~ monobasic pH 7.4, 20 mM KH~2~PO~4~ dibasic pH 7.4, 0.5 mM EDTA, 10% glycerol, 0.5% NP40, 1 mM DTT, 200 mM KCl, 1 mg/ml bovine serum albumin (BSA) and protease inhibitors). GST, GST-RAD51 (R51T1-R51T4) were preincubated with dry sepharose beads and R51/B2 buffer for 30 min at room temperature. Then, APRIN was added to the mix and incubated for 1 h at 4°C. Complexes were washed three times with R51/B2 buffer without BSA. Proteins were visualized by Western blotting using the indicated antibodies.

Immunoprecipitation analysis {#SEC2-7}
----------------------------

Purified APRIN and RAD51 were incubated for 15 min at 37°C in IP150 buffer (50 mM Tris--HCl pH 7.5, 150 mM NaCl, 0.5% NP40 and protease inhibitors). Flag antibodies were then added to the mix and incubated for 20 min at 4°C. Dry washed Protein A/G Ultralink resin (Thermo Scientific) was added to the mix and incubated 20 min at 4°C. Complexes were washed four times with IP150 buffer and proteins were visualized by Western blotting with the indicated antibodies. Purified APRIN and PALB2 or BRCA2 immunoprecipitations were processed as described above with the appropriate antibodies (Table [2](#tbl2){ref-type="table"}).

###### Antibodies

  Name               Species   Cat\#       Company                     WB       IP       IF       Other
  ------------------ --------- ----------- --------------------------- -------- -------- -------- -------
  PDS5B              Rabbit    A300-538A   Bethyl                      1:2500   1:5000            1:50
  RAD51              Rabbit    sc-8349     Santa Cruz                  1:5000            1:400    
  PALB2              Rabbit    A301-246A   Bethyl                      1:2500   1:5000            
  HIS                Mouse     631 212     Clontech                    1:2500                     
  FLAG               Mouse     F3165       Sigma                       1:5000   1:5000            
  pSMC1 pS306        Rabbit    4029        Cell Signaling Technology                     1:100    
  BRCA2              Mouse     Ab-1        Calbiochem OP95             1:1000                     
  DNA-PKCs Ser2056   Rabbit    ab18192     ABCAM                                         1:500    
  H2AX pS139         Mouse     05-636      Millipore                                     1:6000   

DNA-binding assays {#SEC2-8}
------------------

In competition assays, APRIN was added at the indicated concentration to a mix containing 25 nM of 32P-labeled DNA structures (ssDNA, double-strand (ds) DNA, (SA) splayed arms, Holliday junctions (HJ) and D-loop structures) and specific binding buffer (1× APRIN binding buffer (25 mM MOPS, 0,2% tween, 40 mM KCl) and 1 mM MgCl2). The mix was incubated at 37°C for 10 min. Then, complexes were fixed with 0.5% glutaraldehyde during 15 min and reactions were loaded onto a 0.8% Tris/Borate/EDTA (TBE) 1× agarose gel, run at 65 V, dried onto DE81 filter paper and Whatman paper and then visualized by autoradiography. Quantifications were made on a phosphorimager system (Fuji). In DNA binding assays, the same reactions were performed using 50 nM of the indicated oligonucleotide constructs. Sequences of each oligonucleotide are found in Table [3](#tbl3){ref-type="table"}.

###### Primers used for DNA probes and their sequences

  Structures        Primers
  ----------------- ---------------------------------------------------------------------------------------------
  ss DNA            JYM 925
  ds DNA            JYM 925, JYM 945
  SA                JYM 925, JYM 926
  D-loop            JYM 1745, JYM 1395, JYM 1396
  HJ                JYM,925 JYM 926, JYM 927, JYM 928
  **Oligo names**   **Sequence**
  JYM925            GGGTGAACCTGCAGGTGGGCAAAGATGTCCTAGCAATGTAATCGTCAAGCTTTATGCCGT
  JYM926            ACGCTGCCGAATTCTACCAGTGCCAGCGACGGACATCTTTGCCCACCTGCAGGTTCACCC
  JYM927            ACGGCATAAAGCTTGACGATTACATTGCTACATGGAGCTGTCTAGAGGATCCGACTATCG
  JYM928            CGATAGTCGGATCCTCTAGACAGCTCCATGGTCGCTGGCACTGGTAGAATTCGGCAGCGT
  JYM945            ACGGCATAAAGCTTGACGATTACATTGCTAGGACATCTTTGCCCACCTGCAGGTTCACCC
  JYM1395           GCCAGGGACGGGGTGAACCTGCAGGTGGGCGGCTGCTCATCGTAGGTTAGTATCGACCTATTGGTAGAATTCGGCAGCGTCATGCGACGGC
  JYM1396           GCCGTCGCATGACGCTGCCGAATTCTACCACGCTACTAGGGTGCCTTGCTAGGACATCTTTGCCCACCTGCAGGTTCACCCCGTCCCTGGC
  JYM 3452          GGACTCCAGGTCCAGGACCGCTTTTTGCGCGCGCTTTTTGCGGGAGGTCCAGCTGTCCACCTCC
  JYM 3453          GGAGGTGGACAGCTGGACCTCCCGCAAAAAGCGCGCGCAAAAAGCGGTCCTGGACCTGGAGTCC

Complementary single-strand annealing reactions {#SEC2-9}
-----------------------------------------------

Reactions (10 μl) contained denatured 32P-labeled dsDNA (50 nM) with APRIN and/or BRCA2 at the indicated concentrations, in reaction buffer (25 mM MOPS pH 7, 60 mM KCl, 0,2% Tween, 1 mM DTT, 1 mM CaCl~2~). Incubation was performed at 37°C for 15 min. The reaction products were deproteinized by the addition of one-fifth volume of PK buffer (20 mM Tris--Cl pH 7.5 and 2 mg/ml proteinase K) followed by a 30 min incubation period at 37°C. Labeled DNA products were analyzed by electrophoresis (8% polyacrylamide gel electrophoresis gel with TBE1× buffer, run at 150 V for 3 h). The gel was dried and visualized by autoradiography. Quantifications were made on a phosphorimager system.

FAM/BHQ experiments {#SEC2-10}
-------------------

Reactions were carried out in a 96-well LUMITRAC 200 white in a 100 μl final volume. Fluorescence was monitored with a Cytation 5 Cell Imaging Multi-Mode Reader (BioTek). The wavelengths were chosen according to IDT i.e. 494 nM for excitation and 520 nM for emission.

Reactions with or without APRIN in a reaction buffer (25 mM MOPS pH 7, 20 mM KCl, 0,2% Tween, 2 mM DTT, 1 mM CaCl2) were incubated during 2 min at 25°C during which the basal fluorescence was measured every 6 s. After this timepoint, 20 μl of FAM-oligonucleotide was injected to the reaction and fluorescence was measured during 15 min every 6 s. Then, the BHQ-oligonucleotide was added to the reaction and fluorescence was measured during 20 min every 6 s. Oligonucleotide sequences are found in Table [4](#tbl4){ref-type="table"}.

###### FAM/BHQ oligonucleotide sequences obtained from IDT

        Sequence
  ----- ---------------------------------------------
  FAM   5′- 56-FAM/ATAGTTATGGTGAGGACCCCTTTGTTTC-3′
  BHQ   5′- GAAACAAAGGGGTCCTCACCATAACTAT/3BHQ_1/-3′

Biotin pull-down assay {#SEC2-11}
----------------------

Magnetic beads (Roche) bound to a 5′-biotinylated ssDNA polydT 83-mer (corresponding to the final concentration of 1 mM nucleotide) were pre-incubated with a blocking buffer (25 mM Tris--acetate pH 7.5, 40 mM KOAc, 1 mM DTT, 0.02% Igepal and 10 mg/ml BSA) for 20 min at 37°C. The beads were captured with the magnetic particle separator, washed twice with reaction buffer (25 mM Tris--Acetate pH 7.5, 40 mM KOAc, 1 mM DTT, 0.02% Igepal, 1 mg/ml BSA, 5 mM ATP and 0.5 mM MgCl2) and resuspended in the same buffer. hRPA was added and the reaction was incubated for 5 min at 37°C. Then RAD51 was added and the reaction was incubated for 5 min at 37°C. Next, APRIN was added to the reaction for a final volume of 20 μl for 30 min at 37°C. The beads were captured and were washed twice with 500 μl of washing buffer (25 mM Tris--Acetate pH 7.5, 40 mM KOAc, 1 mM DTT, 0.02% Igepal, 5 mM ATP and 0.5 mM MgCl2). Finally, 15 μl of Laemmli buffer was added and beads were heated 5 min at 95°C. The beads were captured again and the supernatants were loaded onto a 8% sodium dodecyl sulphate-polyacrylamide gel electrophoresis Ruby (Invitrogen) and visualized by ultraviolet (UV).

NHEJ *in vitro* reporter assays {#SEC2-12}
-------------------------------

As previously described ([@B28]), a linearized, ^32^P-end labeled pBluescript was incubated for the indicated times with a nuclear extract derived from HeLa cells treated with a scrambled siRNA or an siRNA directed against APRIN (siRNA sequences are found in Table [5](#tbl5){ref-type="table"}).

###### siRNA and shRNA sequences

            Sequence
  --------- -----------------------------------------------------------
  shAPRIN   CCGGCCAGAGTATGTTGTTCCATATCTCGAGATATGGAACAACATACTCTGGTTTTT
  siAPRIN   GAACAAUCAAUAGAUGGA
  si53BP1   ON-TARGETplus Human TP53BP1 siRNA Dharmacon L-003548

Cell fractionation {#SEC2-13}
------------------

3 × 10^6^ cells were washed with PBS and resuspended in 200 μl of solution A (10 mM HEPES at pH 7.9, 10 mM KCl, 1.5 mM MgCl2, 0.34 M sucrose, 10% glycerol, 1 mM DTT, 10 mM NaF, 1 mM Na~3~VO~4~ and protease inhibitors). Triton X-100 was added to a final concentration of 0.1%, and the cells were left on ice for 5 min. Cytoplasmic proteins (S1) were separated from nuclei (P2) by low-speed centrifugation (1400 *g* for 4 min).

Isolated nuclei were washed three times with solution A and lysed in 200 μl of solution B (3 mM EDTA, 0.2 mM Ethylene glycol-bis(2-aminoethylether)-N,N,N\',N\'-tetraacetic acid (EGTA), 1 mM DTT and protease inhibitors). After a 30 min incubation at 4°C, soluble nuclear proteins (S2) were separated from chromatin (P2) by centrifugation (1700 *g* for 4 min). Isolated chromatin was washed three times with solution B and separated by centrifugation (1700 *g* for 4 min). Finally, chromatin was resuspended in 200 μl of Laemmli buffer and sheared by sonication. Proteins were visualized by Western blotting using the indicated antibodies.

Immunofluorescence {#SEC2-14}
------------------

For DNA-PKcs foci, U2OS cells were treated with neocarzinostatin (Sigma - \#9014-02-2) 100 ng/ml during 1 h. Cells were washed two times with PBS and fixed with 4% PFA and cold methanol. Cells were then permeabilized with Triton-X (Sigma) and quenched with Sodium borohydride. After blocking in a BSA/Goat Serum mix, cells were incubated with DNA-PKcs Ser2056 antiboody for 2 h. After washing, cells were incubated with secondary antibody for 1 h at room temperature. After three more washes, cells were mounted in with the ProLong^®^ Gold Antifade Mountant with DAPI (Life Technologies Inc., \#P-36931).

Laser-induced DNA damage and time-lapse microscopy analysis {#SEC2-15}
-----------------------------------------------------------

SKOV3 cells stably expressing GFP-APRIN and HeLa cells transiently expressing GFP-APRIN or deletion mutants were grown in 35-mm fluorodishes (World Precision Instruments, Inc.) and micro-irradiated along a track in cell nuclei using a 405 nm UV-laser coupled into a Leica TCS SP5 II confocal microscope driven by Leica LAS AF software. The settings were as follows: laser power output 100%, format 512 × 512 pixels, scan speed 100 Hz, scan iterations 5, mode bidirectional, zoom 2×. In the case of HeLa cells, the GFP-APRIN constructs (1 μg) were transfected overnight with Effectene transfection reagent (Qiagen) prior to microirradition. Cells were then fixed at the indicated time points and processed for immunofluorescence according to Cell Signaling Technology general protocol with antibodies to SMC1 pS360, RAD51 and H2AX pS139. Secondary antibodies Alexa Fluor 568 (1:1000, Invitrogen, \#A-11004) was used to detect γ-H2AX and Alexa 647 (1:1000, Invitrogen, \#A-21244) for p-SMC1 and RAD51 staining. Coverslips were mounted onto slides with ProLong^®^ Gold Antifade Mountant with DAPI (PLife Technologies Inc., \#P-36931). Images were acquired at a magnification of 63× using a Leica CTR 6000 microscope followed by background subtraction and deconvolution with the Volocity software v 6.0 (PerkinElmer).

For time-lapse microscopy, 250 000 cells from the indicated HeLa cell lines were seeded onto 35-mm fluorodishes and transfected 20 h later with 1 μg mCherry-PCNA and GFP-APRIN or YFP-PALB2-WT with Effectene transfection reagent (Qiagen). The next day, cells were micro-irradiated with the point-bleach mode using the confocal system and settings described above. The recruitment of GFP-APRIN or YFP-PALB2 to laser-induced DNA damage sites was then monitored over time by imaging cells every 2 min for 1 h. The fluorescence intensity of the indicated DNA constructs at DNA damage sites relative to an unirradiated area was quantified and plotted over time. Data show the mean relative fluorescence intensity ± S.E. of ∼50 cells per condition from at least three independent experiments.

Generation of CRISPR/Cas APRIN deletion clones in CH12F3-2 cells {#SEC2-16}
----------------------------------------------------------------

Guide RNA sequences were designed using CRISPR Design Tool (<http://tools.genome-engineering.org>). Two strategies with two gRNA designed to produce a genomic deletion were used, either targeting exon 3 (for a 54 bp deletion) or exon 4 and exon 6, producing a 964 bp DNA deletion (See Table [6](#tbl6){ref-type="table"} for sequences). Each gRNA sequence and their complement were ligated in pX458 (pSpCas9(BB)-2A-GFP, Addgene \#48138). Cells were cotransfected with the two guides in pX458 by electroporation using nucleofector kit V (Amaxa) following the manufacturer\'s protocol. Single GFP positive cells were sorted in 96-well plates 24 h post-transfection. DNA from the resulting clones was extracted with DirectPCR (cell) (Viagen) + Proteinase K (Biobasic) following the manufacturer\'s protocol. APRIN knock-out clones were identified by PCR using primers listed in Table [7](#tbl7){ref-type="table"}. Knock-out clones were confirmed by western blot using rabbit anti-PDS5B antibody.

###### Guide RNAs used for CRISPR-Cas deletion of APRIN exons

                Sequence
  ------------- -----------------------------
  Exon 3 gRNA   5′- AGTTTATCGGGAGACGTGTA-3′
  Exon 3 gRNA   5′- TGATAAAGATGTTCGTTTAC-3′
  Exon 4 gRNA   5′-GTTTATAACAAGGCAACTAA-3′
  Exon 6 gRNA   5′-TGAAGGTGATACCGTATCTC-3′

###### PCR primers to validate CRISPR-Cas deletions

                                 Sequence
  ------------------------------ --------------------------------
  Exon 3 deletion forward        5′-GACCAGGACTCTGAAGAGGAAAA-3′
  Exon 3 deletion reverse        5′-GTCCAGGCAATACAACAGAA-3′
  Exon 4 to 6 deletion forward   5′-TCTTCCATGTTTACAAAGTTGGTG-3′
  Exon 4 to 6 deletion reverse   5′-CATTTCACATACCTTATGGGCAGG-3′

Monitoring class switch recombination {#SEC2-17}
-------------------------------------

IgM to IgA switching was assayed in CH12F3-2 cells activated for 3 days with 1 ng/ml TGF-β1, 10 ng/ml IL-4 and 1 μg/ml agonist anti-CD40 (BD). IgA expression was measured by flow cytometry using anti-mouse IgA-PE antibody in which stimulation with anti-CD40, TGF-β1 and IL-4 induces AID and isotype switching to IgA.

Annexin staining {#SEC2-18}
----------------

0.5 × 10^6^ cells were resuspended in 100 μl Annexin V binding buffer (BD Biosciences) and stained with 3ul APC-Annexin V (BD Biosciences) for 15 min at room temperature. A total of 400 μl Annexin V binding buffer was then added with 2 μg/ml Propidium Iodide (Bioshop). Annexin V positive cells were acquired on a FACSCalibur (BD Biosciences).

Zebrafish husbandry, embryo collection and embryo staging {#SEC2-19}
---------------------------------------------------------

Use of zebrafish in this study was approved by the Dalhousie University Animal Care Committee (protocol no. 11--129). Zebrafish were maintained according to standard protocols ([@B29]). Embryos were collected and grown in E3 embryo media (5 mM NaCl, 0.17 mM KCl, 0.4 mM CaCl~2~ and 0.16 mM MgSO~4~, pH 7.5, supplemented with 1 × 10-5% Methylene Blue \[v/v\]) at 28.5°C. The casper (roy orbison-/-; nacre-/) double mutant zebrafish line was employed to avoid any autofluorescence that might impede direct visualization of fluorescent leukemia cells ([@B30]). Embryos were developmentally staged according to standard protocol ([@B29]).

Xenotransplantation of APRIN depleted cells into Zebrafish embryos, dissociation and immunofluorescence {#SEC2-20}
-------------------------------------------------------------------------------------------------------

Using a protocol adapted from Haldi *et al.* ([@B31]), mutant casper zebrafish embryos at 48 h post fertilization (hpf) were anaesthetized with 0.090 mg/ml Tricaine (Sigma-Aldrich) and used for cell transplantation. Briefly, CM-DiI-labeled HeLa cells were re-suspended in Fetal Bovine Serum (FBS) and loaded into a pulled glass micropipette and ∼50 cells were delivered, as a single injection, into the yolk sac of each embryo (Injection conditions: 0.1 seconds, 2.5 psi) using a PLI-100A Pico-Liter Injector (Warner instruments) while under observation using a Zeiss SteREO Discovery.V8 microscope. Following injection, embryos were allowed to recover at 28°C for 1 h before transfer to 35°C where they remained for the experiment.

At 48 h post injection (hpi), only embryos with a uniform fluorescent cell mass at the site of injection were used for proliferation studies. Embryo xenotransplanted with human cancer cells were then maintained in groups of 15--20 and drugs were added directly to the fish water, at indicated concentrations and embryos were incubated for 48 h until 144hpf. Embryos treated with vehicle (0.1% Dimethyl sulfoxide (DMSO)) served as a negative control for drug efficacy ([@B32]). For the fluorescence imaging, a filter with excitation/emission wavelengths of 550/605 nm was used and all embryos were photographed under the same settings.

To determine rate of cellular proliferation *in vivo* positively injected embryos were placed into groups of 15--20 embryos and euthanized by a Tricaine overdose at the time intervals: 48hpi (0hpt) and 96hpi (48hpt) and dissociated into a single cell suspension using the protocol outlined by Corkery *et al.* ([@B32]). The dissociations were analyzed using the inverted Axio Observer Z1 microscope to determine the number of fluorescent cells per embryo, and cellular proliferation was represented as a fold change of the number of fluorescent cells present at 48hpi.

Statistical Analysis were performed with GraphPad Prism 5.0. For parameter comparisons between groups, an unpaired two-tailed Student\'s *t*-test or one-way ANOVA followed by Dunnett\'s multiple comparison test were used when appropriate. *P*-values of \<0.05 were considered significant. Results are reported as mean ± SEM.

Patients and tissue specimens {#SEC2-21}
-----------------------------

Tumor samples were obtained from patients who underwent surgery for ovarian cancer at the Department of Gynecologic Oncology Centre Hospitalier de l\'Université de Montréal (CHUM). A gynecologist-oncologist established disease stage as defined by the Federation International of Gynecology and Obstetrics (FIGO). An independent pathologist reviewed tumor histopathology and grade. Tissue selection criteria for this study were based on independent confirmation of high grade serous (HGS) histopathology in samples from chemotherapy-naive patients. Samples were collected between 1992 and 2012. Patient disease free survival was calculated from the diagnostic date until the first progression or last follow-up. Clinical data on progression-free interval were defined according to computed tomographic imaging alone or in combination with blood CA125 levels. Patient overall survival was defined as the time from surgery to death from ovarian cancer or last follow-up. Patients known to be still alive at time of analysis were censored at time of their last follow-up.

Epithelial serous ovarian tumor tissue microarray (TMA) {#SEC2-22}
-------------------------------------------------------

A gynecologic pathologist reviewed all cases. The grade and type of ovarian carcinoma were identified and areas of interest were marked on slides. Two cores of 0.6 mm for each tissue sample were arrayed onto one recipient paraffin block. This tissue array was composed of cores from 213 HGS tumors (two cores per patient sample) and was built on two recipient blocks. The tumor tissue microarray (TMA) was then sectioned, stained with hematoxylin-eosin and subjected to another review of tissue pathology to verify the presence of tumor material in each core. Four patients were removed from analysis after pathology review because they did not match with the inclusion criteria.

Immunofluorescence studies on TMA {#SEC2-23}
---------------------------------

We produced an epithelial mask using several specific epithelial antigens to distinguish stromal and epithelial components within tissue. To ensure coverage of all epithelial cells we used a cocktail of CK18, CK19 and CK7 that were all labeled to emit in the orange channel (AF546). APRIN was labeled to emit in the red channel (Cy5) and slides were also stained with DAPI (blue) to identify nuclei. This allowed us to distinguish specific staining of APRIN in the nucleus and cytoplasm of epithelial cells. Specifically, antigen retrieval was carried out with Cell Conditioning 1 using the Bench Mark XT automated stainer (Ventana Medical System Inc.). Primary antibody against APRIN was diluted 1:50 in PBS and incubated at 37°C for 60 min. The following steps were manually done on the bench (while previous steps were performed using the BenchMark XT automated stainer (Ventana Medical System Inc.)) under conditions to protect slides from light. Secondary fluorescent antibody against APRIN was incubated for 45 min at room temperature (RT): anti-mouse Cy5 (, Life Technologies Inc., \#A10524) diluted 1:250 in 1× PBS. TMA slides were then blocked for 60 min with Mouse-On-Mouse blocking reagent (one drop in 250 μl PBS, MKB-2213, Vector Laboratories, CA, USA). Slides were subsequently incubated for 90 min at RT with a mix of anti-CK18, anti-CK19 and anti-CK7 (1:100 in 1× PBS) and then 45 min at RT with secondary fluorescent anti-mouse AF546 (Life Technologies Inc., \#A10036). Finally, slides were incubated 15 min at RT with a 0.1% (w/v) solution of Sudan Black in 70% ethanol to quench tissue auto-fluorescence. Slides were mounted with the ProLong^®^ Gold Antifade Mountant with DAPI (Life Technologies Inc., P-36931). Between each step, except after the blocking steps, TMA slides were washed twice with 1× PBS. Slides were stored at 4°C and scanned the next day. A negative control TMA slide was done in parallel and incubated with 1× PBS in place of all primary antibodies.

Staining quantification of TMA {#SEC2-24}
------------------------------

The staining and scoring were performed blinded to the study end-point. The tissue sections were scanned with a 20 × 0.75 NA objective with a resolution of 0.3225 mm with the Olympus microscope and VS110 slide scanner linked to an OlyVia^®^ image viewer software (xvViewer.exe). Fluorescent staining was then quantified by the VisiomorphDP software (Visiopharm, Denmark) allowing for automated image analysis. The staining via CK18/CK19/CK7 markers was used to limit the analysis to epithelial areas as the region of interest \#1 (ROI \#1), while DAPI served to circumscribe nuclei compartment. Cores were manually reviewed and surrounding tissues with necrosis or inflammatory zones were removed from the analysis. In each TMA core, APRIN fluorescence was measured and a mean fluorescence intensity (MFI) score was calculated in the whole epithelial cell compartment as well as in nuclei of epithelial cells more specifically. Continuous MFI values were then collected by the VisiomorphDP software and transferred to Excel files to define epithelial and nuclear APRIN variable expression. The positive and negative signals were based on designated threshold values (mean intensities + standard deviation) and used to calculate the frequency of positive nuclei per core. The average MFI of both tumor cores from the same patient was used for analysis.

Statistical analysis in TMA experiments {#SEC2-25}
---------------------------------------

All statistical analyses were performed using SPSS software version 16.0 (SPSS Inc., Chicago, IL, USA) where *p* = 0.05 were deemed significant. APRIN expression thresholds of 1400 were determined by the receiver operating characteristic (ROC) curve. Survival curves (overall survival and disease free survival) were plotted by the Kaplan-Meier estimator, compared using the log rank test and analyzed for significant differences. The Spearman\'s correlation analysis (two-tailed) was used to obtain correlation with clinical data and biomarker.

RESULTS {#SEC3}
=======

APRIN is recruited to laser-induced DNA damage sites {#SEC3-1}
----------------------------------------------------

Brough *et al.* have shown that APRIN was present at, or near DNA damage sites using chromatin immunoprecipitations ([@B23]). In order to get more insight into the dynamics of this recruitment, we studied the localization of APRIN after DNA damage and compared it to that of RAD51 and p-SMC1, a member of the cohesin complex with a role in DNA repair ([@B33]). Thus, we explored the recruitment of APRIN after a laser-induced damage in a GFP-APRIN SKOV3 stable cell line. Using immunofluorescence time course analysis of recruitment after DNA damage, we found that APRIN is recruited to the damage sites 15 min after release from laser-track. We compared this recruitment to that of p-SMC1 and showed similar recruitment (within 15 min after the damage) (Figure [1A](#F1){ref-type="fig"}). We showed that APRIN was recruited before RAD51 protein, known to be a marker of homology-directed DNA repair. Moreover, we found that APRIN presents, together with RAD51, a peak accumulation at 60 min post-damage (Figure [1A](#F1){ref-type="fig"}). These results are in correlation with a previous study showing a prominent recruitment of RAD51 60 min after DNA damage ([@B34]).

![APRIN is recruited to laser-induced DNA damage sites and its depletion impacts the recruitment of PALB2 to DNA damage sites. (**A**) Representative images of laser-irradiated SKOV3 GFP-APRIN (green) cells and subjected to immunofluorescence procedures for detection of p-SMC1 (yellow, left) or RAD51 (yellow, right) and γ-H2AX (red), at different times post-DNA damage (indicated at the top of each panel). DAPI (blue) represents the nucleus. (**B**) Quantitative evaluation and representative live-cell images (**C**) of APRIN recruitment kinetics in S-phase HeLa cells co-transfected with GFP-APRIN and mCherry-PCNA after laser microirradiation. (**D**) YFP**-**PALB2 recruitment to laser-induced DSBs is diminished in shAPRIN cells.](gkw921fig1){#F1}

To examine the functional relevance of APRIN recruitment, we used quantitative microscopy on live cells. Briefly, we generated localized DNA damage in a specific region within the nucleus and followed the recruitment of GFP-APRIN by taking pictures every 2 min during 1 h. Interestingly, we show that S/G2 phase cells (as detected by mCherry-PCNA distribution) exhibited 1.4-fold greater median APRIN recruitment to laser-induced DNA damage (Figure [1B](#F1){ref-type="fig"} and [C](#F1){ref-type="fig"}).

We monitored subsequently if the depletion of APRIN could have an impact on PALB2 or the opposite. APRIN depletion leads to a reduction, but not impairment, of PALB2 recruitment to laser-induced DSBs suggesting a functional relationship between these proteins (Figure [1D](#F1){ref-type="fig"}). ShRNA knockdown of PALB2 did not affect APRIN recruitment (Supplementary Figure S1A). We found that APRIN and RAD51 colocalized at laser-induced DNA damage (Supplementary Figure S1B). These results suggest that APRIN is recruited to DNA damage sites and possibly function in HR with RAD51 and PALB2.

APRIN interacts directly with RAD51, PALB2 and BRCA2 {#SEC3-2}
----------------------------------------------------

Using immunoprecipitation analysis from cell extracts, it has been previously shown that APRIN interacts *in vivo* with BRCA2, PALB2 and RAD51 ([@B23]). Having established that APRIN influences PALB2 recruitment and co-localized with RAD51, we scrutinized if APRIN could interact directly with HR proteins using purified components. To do so, we purified APRIN to near homogeneity by double affinity (Figure [2A](#F2){ref-type="fig"} and Supplementary Figure S2A), from Spodoptera frugiperda insect cells (Sf9). The protein was pure as judged by Coomassie blue and silver staining (Supplementary Figure S2B). Using co-immunoprecipitation assays of purified proteins, we observed that human RAD51 and APRIN bind directly with each other (Figure [2B](#F2){ref-type="fig"}). APRIN interacts on two separate regions of RAD51 (amino acids 1--100, and 101--184, the latter bearing the RAD51 ATPase domain) (Figure [2C](#F2){ref-type="fig"} and [D](#F2){ref-type="fig"}). Furthermore, using the same assays we showed that APRIN interacted directly with full-length proteins PALB2 (Figure [2E](#F2){ref-type="fig"}) and BRCA2 (Figure [2F](#F2){ref-type="fig"}). These results identify APRIN as a new component of the HR machinery.

![APRIN physically interacts to RAD51, PALB2 and BRCA2. (**A**) SDS-PAGE gel of purified His/Flag APRIN stained with Coomassie blue. Lane 1, Molecular weight markers; Lane 2, APRIN purified protein (250 ng). (**B**) Co-immunoprecipitation of purified APRIN and RAD51 using antibodies against histidine tag (His), followed by western blotting with anti-His antibody. (**C**) Scheme of the RAD51 deletion variants fused to GST. (**D**) GST alone or GST-tagged RAD51 fragments purified from *Escherichia coli* were incubated with APRIN. Sepharose beads were used to immunoprecipitate complexes. (**E**) Co-immunoprecipitation of purified APRIN (500 ng) and PALB2 (500 ng) using antibodies against PALB2, followed by western blotting with anti-APRIN or anti-PALB2 antibodies. (**F**) Co-immunoprecipitation of purified APRIN (500 ng) and BRCA2 (100 ng) using antibodies against APRIN, followed by western blotting with APRIN or BRCA2 antibodies.](gkw921fig2){#F2}

Purified APRIN binds different DNA intermediates of HR {#SEC3-3}
------------------------------------------------------

One of the characteristics of HR mediators is their ability to bind DNA with specific affinity for ssDNA. APRIN bears AT hook domains known to be involved in DNA binding (Supplementary Figure S2C) ([@B22]) and is a chromatin-associated protein (Supplementary Figure S2D). These observations suggested that APRIN could also be implicated in DNA repair via its likely interaction with DNA. Using DNA electrophoretic mobility shift assays (EMSA), we showed that APRIN can indeed bind diverse HR intermediates, such as ssDNA, SA, HJ or displacement-loop (D-loop), but surprisingly not dsDNA (Supplementary Figure S3). We then analyzed the relative affinity of APRIN for the different DNA structures using competition assays. Thus, we mixed all five DNA substrates in the same reaction and quantified APRIN--DNA interactions. At 5 nM of APRIN, 60% of D-loop was bound, followed by ssDNA and splayed arms (15--20%), compared with 1--15% for all other DNA substrates (Figure [3A](#F3){ref-type="fig"} and [B](#F3){ref-type="fig"}). Hence, we showed that APRIN binds preferentially D-loop structures over ssDNA, SA and HJ. Together, these results reveal the ability of APRIN to bind different DNA substrates, with a strong preferential affinity for D-loop structures.

![APRIN binds DNA with preference for single-strand (ss) DNA and D-loop structures and enhances RAD51 mediated D-loop formation. (**A**) Competition electrophoretic mobility shift assays (EMSAs) were performed with purified APRIN and a mix containing equal quantities of ssDNA, double-strand (ds) DNA, splayed arms (SA), Holliday junctions (HJ), Displacement-loop (D-loop) on 8% acrylamide gel. (**B**) Quantification with Phosphor Imager of the EMSAs from four independent experiments. Error bars represent the corresponding standard error. (**C**) RPA displacement assay. RPA bound to a ssDNA oligonucleotide prevents RAD51 assembly (lane 5) whereas addition of APRIN (20--80 nM) stimulates RAD51 filament formation in presence of RPA (lanes 6--9). (**D**) Scheme of the different steps of D-loop formation. (**E**) D-loop formation mediated by APRIN alone (lane 2), RAD51 alone (lane 3) and a titration of APRIN (lanes 4--8). (**F**) Phosphor Imager quantification of the results from three independent experiments. Error bars represent the corresponding standard error.](gkw921fig3){#F3}

To further characterize the DNA binding domains of APRIN, we purified to near homogeneity five protein fragments (named A1 to A5) from bacteria, spanning APRIN coding sequence (Supplementary Figure S4A and B). Using EMSA, we found that 50--100 nM of A2 and A4 could bind ssDNA whereas A1, A3 and the C-terminal region (A5) do not bind DNA (Supplementary Figure S4C). To understand the function of these domains in the recruitment of APRIN to DNA damage sites, we created different versions of APRIN lacking the A2, A4 or A5 regions (Supplementary Figure S4D). Due to the presence of a NLS on the C-terminal domain of APRIN, we also complemented the A5-deleted mutant with the NLS from nucleoplasmin. Laser track experiments showed that although all mutants were still recruited to DNA damage sites, the mutants lacking A2 or A4 fragments were less efficiently recruited (Supplementary Figure S4E). These results suggest that the A2 and A4 regions promote APRIN recruitment to DNA damage sites.

APRIN is a new HR mediator that stimulates RAD51-mediated D-loop formation {#SEC3-4}
--------------------------------------------------------------------------

APRIN is important for efficient HR ([@B23]). Since we have shown that APRIN is recruited to damage sites, interacts directly with RAD51 and binds DNA, we tested whether it could be a mediator of HR by its ability to counteract the RPA inhibitory effect on RAD51. Indeed, prior to strand invasion, the ssDNA binding protein RPA must be displaced from the ss tail of the newly resected DSB to allow RAD51 filament formation. Such function is accomplished by BRCA2 or PALB2 recombination mediators to promote the presynaptic filament assembly ([@B10]).

The addition of 400 nM totally blocks the association of RAD51 with ssDNA-coupled beads. In the presence of RPA, RAD51 loading on ssDNA coupled beads was strongly inhibited (Figure [3C](#F3){ref-type="fig"}, compare lanes 4 and 5). When APRIN was added after RAD51 and RRA, RAD51 gained access to the ssDNA (Figure [3F](#F3){ref-type="fig"}, compare lane 9). These results suggest that APRIN, as PALB2 and BRCA2, is a mediator of HR.

Having establish APRIN as a new HR mediator, we analyzed whether APRIN could enhance RAD51-mediated D-loop formation. We performed D-loop assays, as previously described ([@B35]), using labeled 63 nt probes in presence of saturating concentration of RAD51 (300 nM) and a super-coiled plasmid (pPB4.3) (Figure [3D](#F3){ref-type="fig"}). No product of D-loop was observed with APRIN alone (Figure [3E](#F3){ref-type="fig"}, lane 2). We then quantified strand invasion in presence of increasing concentration of APRIN and RAD51 (Figure [3D](#F3){ref-type="fig"}--[E](#F3){ref-type="fig"}). APRIN stimulated RAD51-mediated D-loop formation by 2-fold. These results suggest that APRIN is a mediator of HR with a role in RAD51 D-loop formation.

APRIN enhances the annealing of complementary single-strands {#SEC3-5}
------------------------------------------------------------

The high affinity of APRIN for ssDNA and its implication in RAD51 D-loop formation led us to investigate next the role of APRIN in complementary-strand annealing. In this assay, we denatured a 100 bp dsDNA fragment. The product was cooled down and APRIN was added or not to the reaction (Figure [4A](#F4){ref-type="fig"}). While low levels of spontaneous strand annealing are observed in the control reaction alone (28%, Figure [4B](#F4){ref-type="fig"}, lane 2), APRIN greatly enhanced the formation of dsDNA (∼100% for 20 nM of APRIN, Figure [4B](#F4){ref-type="fig"}, lane 9 and Figure [3C](#F3){ref-type="fig"}), indicating that it promotes annealing of complementary ssDNA. To confirm this result, we designed a system implicating two-labeled complementary DNA probes. One of the two oligonucleotides was labeled with a fluorescent fluorescein (FAM) moiety at the 5′ terminus and a complementary oligonucleotide bore a Black Hole Quencher (BHQ). Briefly, at 494 nm the FAM is excited and emits light at 592 nM. When the BHQ is sufficiently near to the FAM, it blocks this phenomenon leading to an absence of emission (Figure [3D](#F3){ref-type="fig"}). Having established a condition where auto-quenching was low, we added APRIN to the reaction. We found that APRIN efficiently accelerates the annealing of complementary DNA strands (Figure [3E](#F3){ref-type="fig"}).

![APRIN is proficient in ss annealing. (**A**) Scheme of the different steps of the homologous strand-annealing assay. (**B**) APRIN promotes ss annealing. Lane 1, purified 60-bp duplex DNA (dsDNA). Reactions contained denatured 60-bp duplex DNA in buffer with no protein (lane 2; den. DNA: denatured DNA) or with purified APRIN (1--20 nM), lanes 3--9. (**C**) Phosphor Imager quantification of the annealing from three independent experiments. Error bars represent the corresponding standard error. (**D**) Scheme of the FAM/BHQ annealing experiment. In brief, APRIN was added to the reaction and the basal fluorescence was analyzed during 2 min. Then, 5′-FAM (6-carboxyfluorescein amidite), a fluorescent dye for labeling oligonucleotides, was added to the reaction for 15 min. The FAM is reactive, and has an absorbance maximum of 494 nm with an emission maximum of 520 nm. Lastly, BHQ (Black Hole Quencher) homologous oligonucleotide was added to the reaction after which the fluorescence was measured every 6 s with a Cytation5 BioteK plate reader. (**E**) Quantification of the results from three independent experiments. The maximum of fluorescence at *t* = 0 min corresponds to the mean fluorescence during the 15 min of the reaction containing APRIN and the oligonucleotide. Error bars represent the corresponding standard error.](gkw921fig4){#F4}

APRIN enhances complementary-strand annealing in synergy with BRCA2 {#SEC3-6}
-------------------------------------------------------------------

Given that BRCA2 and APRIN interact with each other (([@B23]) and Figure [2F](#F2){ref-type="fig"}) and that APRIN has a strong DNA annealing activity (Figure [2A](#F2){ref-type="fig"}--[E](#F2){ref-type="fig"}), we analysed the impact of this interaction on complementary-strand annealing in presence of BRCA2. It is important to note that APRIN ss annealing activity is more robust than PALB2 (Supplementary Figure S5A and B). We purified human BRCA2 to homogeneity ([@B36]) (Figure [5A](#F5){ref-type="fig"}) and performed further strand annealing experiments. When using purified APRIN and BRCA2 proteins independently and at very low concentration (1 and 0.1 nM respectively), the annealing was enhanced significatively (1.2-fold more compared to no protein) (Figure [5B](#F5){ref-type="fig"} and [C](#F5){ref-type="fig"}). Interestingly, at the same concentrations, APRIN and BRCA2 cooperate to increase annealing to 1.7-fold, the stimulation being stronger than the predicted additive effects (Figure [5B](#F5){ref-type="fig"}). These results suggest that BRCA2 and APRIN have synergistic roles in the synaptic step of HR, which implicates complementary strand annealing.

![APRIN enhances the homologous-strand annealing in synergy with BRCA2. (**A**) Silver-stained SDS page of human BRCA2. (**B**) APRIN and BRCA2 annealing assays. Lane 1, purified 60-bp duplex DNA. Reactions contained denatured 60-bp duplex DNA in buffer with no protein (lane 2; den. DNA: denatured DNA) or with purified APRIN alone (1 nM, lane 3), BRCA2 alone (1 nM, lane 4) or a mixture of APRIN and BRCA2 (lane 5). (**C**) Phosphor Imager quantification of the result from three independent experiments. Error bars represent the corresponding standard error.](gkw921fig5){#F5}

Unlike cohesins, APRIN does not play a role in NHEJ or CSR {#SEC3-7}
----------------------------------------------------------

It has been shown that cohesins are implicated in NHEJ during CSR ([@B17]). Since APRIN is a cohesin binding protein ([@B21]), we reasoned that investigating whether APRIN plays a role in NHEJ and CSR would indicate whether APRIN has cohesin-dependent roles. We first used a cell-free NHEJ assay ([@B28]) that measures the ligation of a 32P-labeled linearized plasmid following incubation with nuclear extracts derived from siRNA control or siRNA APRIN transfected 293T cells (Figure [6A](#F6){ref-type="fig"}). The knockdown of APRIN in 293T cells did not have any impact on NHEJ kinetics *in vitro* compared to the control condition (Figure [6B](#F6){ref-type="fig"}). To confirm this result, we investigated whether APRIN affected DNA-PKcs phosphorylation at Ser2056 *in vivo*, which is correlated with active NHEJ ([@B37]). As expected, DNA-PKcs autophosphorylation level induced by neocarzinostatin treatment was not affected by APRIN depletion as opposed to 53BP1, a key player in the promotion of NHEJ and inhibition of HR ([@B38]), whose knock-down caused reduced DNA-PKcs Ser2056 foci formation (Figure [6C](#F6){ref-type="fig"} and [D](#F6){ref-type="fig"}).

![APRIN is not implicated in non-homologous end-joining (NHEJ) nor switch class recombination (CSR). (**A**) Depletion in 293T using siRNA control (si CTL) or siRNA against APRIN (si APRIN). (**B**) A linearized, ^32^P-end labeled pBluescript was incubated for 30 min with a nuclear extract (125 or 250 ng) derived from 293T cells treated with si CTL (lanes 2--3) or si APRIN (lanes 4--5). (**C**) Immunofluorescence staining of phosphorylated DNA-PKcs in untreated or neocarzinostatin (NCS) treated cells at 100 ng/ml for 1 h. (**D**) Quantification of the number of foci from three independent experiments. Error bars represent the corresponding standard error. (**E**) Mouse B-cell line CH12F3 were depleted from APRIN using the CRISPR-Cas9 method. A7 clone represents a deletion in exon 3. C5 and D1 clones represent deletion of exon 5 and a part of exon 6. (**F**) Quantification of the switching between IgM and IgA. After stimulation with TGFB1, IL-4 and anti-CD40, cells were labeled with anti-IgA and analyzed using FACS. Error bars represent the corresponding standard error.](gkw921fig6){#F6}

We then studied the impact of APRIN depletion on the CSR. To do so, we quantified the switch between IgM and IgA in murine B lymphoma CH12F3 cells. Using the CRISPR-Cas9 method, we eliminated APRIN in CH12F3 cells following two strategies: one consisting in the deletion of exon 3 and the other in the deletion of exon 5 and parts of exon 4 and 6 of APRIN. We selected a single clone of the first strategy (A7) and two from the second (C5 and D1) (Figure [6E](#F6){ref-type="fig"}). The depletion of APRIN in CH12F3 did not have any impact on the cell viability (Supplementary Figure S6A and B). After TGFB1, IL-4 and anti-CD40 stimulation, cells were labeled with an antibody against IgA and analyzed by FACs. We found that APRIN depletion does not have any impact on CSR in CH12F3 cells (Figure [6F](#F6){ref-type="fig"}), supporting an exclusive implication of APRIN in HR.

Depletion of APRIN leads to the sensitization of cells to PARP inhibition Olaparib and Veliparib {#SEC3-8}
------------------------------------------------------------------------------------------------

It has been previously shown that APRIN depletion leads to the sensitization of cells to PARP inhibitors or other DNA damaging agents ([@B23]). Thus, we wanted to examine this concept in a living animal. Hence, we created HeLa cell line stably expressing APRIN shRNA (shAPRIN) (Figure [7A](#F7){ref-type="fig"}). These cells were CM-DiI-labeled and implanted in 48 h post-fertilization zebrafish embryos. Forty-eight hours post-injection, embryos with a uniform mass (indicated by a gray arrow in Figure [7B](#F7){ref-type="fig"}) were treated with the PARP inhibitor Olaparib or vehicle (DMSO) for an additional 48 h, after which tumor size was quantified *ex vivo* by counting tumor cell number following dissociation of engrafted embryos (Figure [7B](#F7){ref-type="fig"}). We found that APRIN-depleted cells showed sensitivity to PARP inhibition Olaparib, leading to a decreased tumor size compared to vehicle treated tumors (Figure [7B](#F7){ref-type="fig"}). We then tested whether HeLa cells depleted for APRIN by shRNA were sensitive to the PARP inhibitor Olaparib as previously described ([@B23]). Using MTT assays, we found that the depletion of APRIN sensitized cells to Olaparib (Figure [7C](#F7){ref-type="fig"}). We also showed that these cells were sensitive to Veliparib, another PARP inhibitor (Figure [7D](#F7){ref-type="fig"}).

![APRIN-depleted HeLa cells are sensitive to PARP inhibitor treatment. (**A**) Western blot showing the depletion of APRIN using APRIN shRNA (shAPRIN) or control shRNA (shCTL). (**B**) Representative bright field and fluorescent images of zebrafish (top) along with the bar graphs showing cellular proliferation *in vivo* (bottom). Uniform fluorescent mass is indicated by the gray arrow. An unpaired two-tailed Student\'s *t*-test or one-way ANOVA followed by Dunnett\'s multiple comparison test were used when appropriate. *P*-values of \<0.05 were considered significant. Results are reported as mean ± SEM. (**C**) Survival curves obtained from MTT assays on shCTL or shAPRIN HeLa cells in presence of PARP inhibitor Olaparib at the indicated concentration. (**D**) Survival curves obtained from MTT assay on shCTL or shAPRIN HeLa cells in presence of PARP inhibitor Veliparib. Error bars represent the corresponding Standard Error. Survival experiments have been performed for 5 days.](gkw921fig7){#F7}

Low levels of APRIN correlate with better survival in high grade serous (HGS) epithelial ovarian cancer patients {#SEC3-9}
----------------------------------------------------------------------------------------------------------------

It has been suggested that APRIN is a potential tumor suppressor since it is downregulated or suppressed in many cancers ([@B39]). Moreover, Brough *et al.* showed that APRIN levels are modulated in accordance to the breast cancer grade of patients. Since APRIN interacts with BRCA2 whose mutations can lead to ovarian cancers, we investigated the expression of APRIN on a TMA containing 207 cases of HGS ovarian cancer cases (Table [8](#tbl8){ref-type="table"}). To specifically assess the impact of APRIN expression on ovarian tumor cells, we performed immunofluorescence double-staining for APRIN and epithelial cytokeratin 7/18/19 (Figure [8A](#F8){ref-type="fig"}) and determined the intensity of APRIN expression per epithelial surface unit (Figure [8B](#F8){ref-type="fig"}). Two groups were created based on a ROC curve analysis (ROC curve is most suitable to determine the optimal cut off values ([@B43])): (i) samples with a MFI of \<1400 were considered as 'low' APRIN expression; (ii) samples with a MFI over 1400, were considered as 'High' APRIN expression (Figure [8C](#F8){ref-type="fig"}). High levels of APRIN (Figure [8D](#F8){ref-type="fig"} and [E](#F8){ref-type="fig"}) in tumor cells were associated with a significantly shorter time of recurrence (mean ± SD: 53.96 ± 7.04 months for low APRIN versus 35.39 ± 4.5 months for high APRIN; *p* = 0.028) (Figure [8D](#F8){ref-type="fig"}) and decreased overall survival (mean ± SD: 86.25 ± 7.9 months for low APRIN versus 56.9 ± 4.6 months for high APRIN; *p* = 0.003) (Figure [8E](#F8){ref-type="fig"}). APRIN expression in tumor cells was also associated with a worse overall survival and correlate with the residual disease as determined by Spearman\'s correlation analysis (Supplementary Table SI).

###### Clinicopathological characteristics of the HGS EOC cores present on the TMA (*n* = 207)

                                                    Median (range) or *n* (%)
  -------------------------------- ---------------- ---------------------------
  Age (years)                                       61 (34--89)
  FIGO stage                       I                13 (6)
                                   II               23 (11)
                                   III              147 (71)
                                   IV               25 (12)
  Debulking                        Optimal          96 (46)
                                   Non optimal      91 (44)
                                   unknown          21 (10)
  Chemotherapy                     platinum-based   191 (92)
                                   taxane alone     2 (1)
                                   unknown          15 (7)
  Follow-up time (months)                           36 (1--156)
  Dis. Progression time (months)                    14 (0--76)

![Low APRIN expression levels are correlated with better survival of ovarian cancer patients. (**A**) Co-expression of APRIN (red) and epithelial cytokeratin-7/18/19 (orange) were analyzed by immunofluorescence. (**B**) APRIN protein expression in tumor cells was quantified by immunofluorescence, and measured for 207 cases of HGS ovarian cancer on TMA. Expression per epithelial surface unit was calculated as the integrated intensity of APRIN in the cytokeratin compartment divided by the number of pixels present in the cytokeratin compartment (bars represent individual cases). (**C**) Representative images of low and high immunofluorescence staining against APRIN in TMA of specimens from ovarian cancer patients. (**D** and **E**) Subjects with low or high APRIN expression (as determined by ROC analysis) were plotted to determine the association between APRIN expression in tumor cells with the time to recurrence (D) or overall survival (E). A receiver operating characteristic (ROC) curve, is a graphical plot that illustrates the performance of binary classifier system as its discrimination threshold is varied. ROC curve is most suitable to determine the optimal cut off values ([@B43]). Significance (P) was determined by log-rank test. *n*, number of patients in low or high APRIN expression group. *N*, total number of patients. MFI: mean fluorescence intensity; RU: relative units.](gkw921fig8){#F8}

DISCUSSION {#SEC4}
==========

In this manuscript, we investigated the activity and interacting partners of APRIN, uncovering novel functions for this protein in HR. Brough *et al.*, suggested that APRIN could be an interface between cohesin and HR proteins. We propose that APRIN could have a direct role in HR and possibly in different steps of the pathway.

Brough *et al.* showed that APRIN colocalizes occasionnally with RAD51 ([@B23]). In this study, we have found that APRIN is recruited to DNA damage using laser-induced DSBs. We showed that APRIN interacts directly with RAD51, PALB2 and BRCA2. It has been previously shown that this complex exists *in vivo* ([@B23]). We hence propose that APRIN could be a new component of this complex. We showed that APRIN enhances RAD51-mediated D-loop formation. Using *in vitro* experiments, we showed that APRIN interacts strongly with DNA, with a marked preference for the D-loop and ssDNA structures mimicking different steps of HR. Moreover, whereas APRIN is unable to stimulate D-loop formation on its own, we showed that it independently stimulates complementary-strand annealing, an activity that is enhanced with the presence of the BRCA2 protein. We believe that this role could explain why the interaction between BRCA2 and APRIN has been found to be S-phase specific ([@B23]).

We found that APRIN is specifically implicated in HR, as it is not involved in NHEJ or CSR. As known, APRIN is a cohesion-interacting factor with roles in cohesion regulation. Previous studies have shown that cohesins are specifically recruited to laser-induced DNA damage ([@B18]). Moreover, Kong *et al.* proposed that the presence of a sister chromatid and/or an additional factor(s) contributes to the cell cycle-specific cohesin-SA2/NIPBL recruitment ([@B19]). The fact that APRIN interacts directly with PALB2 and RAD51 makes it a candidate for the specific recruitment of the cohesin complex to DSB during S/G2 phases. We showed that APRIN is recruited to laser-induced DNA damage sites at the same time as p-SMC1. This recruitment of APRIN is dependent on the A2 and A4 domains. This is in accordance with recent findings showing that APRIN interacts with SMC1 through two distinct domains ([@B40]) which are located on the A2 and A4 fragments. Hence, we postulate that APRIN recruitment to DNA damage sites would be dependent on A2, A4 domains and cohesin. This recruitment is not dependent on PALB2.

The observation that RAD51 protein is recruited after the cohesin reinforce the idea that APRIN could serve as a coordinating platform, proposed by Brough *et al.*, with an important regulatory role in HR. In fact, APRIN can stimulate RAD51-mediated D-loop formation. It can also strongly stimulate annealing of complementary-strand DNA. The latter could help cohesin to trap homologous sister chromatids but our finding that APRIN annealing activity is enhanced by BRCA2 argues against this hypothesis. Nevertheless, the cooperation with BRCA2 further implicates APRIN in the mechanisms of HR. This is in accordance with the observations that APRIN depletion leads to a decrease in RAD51 foci ([@B23]) or to a decrease in the recruitment of PALB2 to DNA damage site (this study).

It has previously been shown that the knockdown of cohesin or its regulatory subunits results in impaired CSR and increased usage of microhomology-based end joining ([@B17]). Nevertheless, depletion of APRIN does not lead to an impaired CSR. Moreover, APRIN is not implicated in NHEJ. Thus, our data reinforce the implication of APRIN exclusively in HR and suggest a model in which APRIN functions in various steps of the mechanism (Supplementary Figure S7). APRIN might also be tightly regulated within this model. Recently, Elia *et al.* have shown that under IR and UV damage APRIN is phosphorylated on its C-terminal part by ATM/ATR ([@B41]). We believe that this modification could be important to modulate the activity of APRIN during HR and to contribute to its cell cycle-dependent activity.

APRIN has been characterized as a candidate tumor suppressor protein ([@B42]). Recent studies have shown that APRIN expression levels are associated with histological grade in breast cancer and the outcome of breast cancer patients treated with DNA-damaging chemotherapy. Here, we examined APRIN expression status in ovarian cancers and showed that low levels of APRIN expression correlate with a better survival of patients. In zebrafish, APRIN depletion leads to sensitization of cells to PARP inhibition in our xenograft experiments, similar to that reported for other chemical agents (such as HU, MMC, Olaparib) ([@B23]), (Olaparib and Veliparib) (this study). Our work therefore helps to understand how APRIN is directly and specifically implicated in HR and identifies APRIN as a potential prognostic factor in ovarian cancer and as a potential target for treatment.
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